Research partially funded by the JKTG Foundation recently appeared recently in the Bulletin of Mathematical Biology.
The research, Intermittent Hormone Therapy Models Analysis and Bayesian Model Comparison for Prostate Cancer, includes work by Heiko Enderling, Ph.D., a researcher with whom JKTG has worked on several projects.
As described in the published abstract, first-line therapy for prostate cancer includes androgen deprivation therapy (ADT), depriving both the normal and malignant prostate cells of androgens required for proliferation and survival.
In recent years, intermittent ADT has been proposed as an alternative to continuous ADT. Several mathematical models with different biological resistance mechanisms have been considered to simulate intermittent ADT response dynamics.
The research compares 13 intermittent dynamical models and assess their ability to describe prostate-specific antigen (PSA) dynamics.
Featured news
Applying nanoparticles and the immune system to fight cancer
JKTG-funded research, Iron oxide nanoparticles inhibit tumor progression and suppress lung metastases in mouse models of breast cancer, appears in the journal ACS Nano and features a collaboration between researchers at Johns Hopkins University School of Medicine and the Hormel Institute at the University of Minnesota.
Ted’s Take: It’s about the money
Money is what seems to drive things and money is what seems to drive organizations too. They all start with an overriding moral goal but after a while things often turn toward more money.
Ted’s Take: The best patient advocate? You.
When you’re a patient, you are kind of vulnerable. You have a problem, are often sketchy about what it is and the potential treatment or therapy needed. The bigger the problem, the more vulnerable you are. This makes you a perfect advocate.
Jayne Koskinas Ted Giovanis
Foundation for Health and Policy
PO Box 130
Highland, Maryland 20777
Media contact: 202.548.0133